Does VUDALIMAB Cause Malignant neoplasm progression? 13 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Malignant neoplasm progression have been filed in association with VUDALIMAB. This represents 19.7% of all adverse event reports for VUDALIMAB.
13
Reports of Malignant neoplasm progression with VUDALIMAB
19.7%
of all VUDALIMAB reports
5
Deaths
11
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VUDALIMAB?
Of the 13 reports, 5 (38.5%) resulted in death, 11 (84.6%) required hospitalization, and 2 (15.4%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VUDALIMAB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does VUDALIMAB Cause?
Anaemia (21)
C-reactive protein increased (20)
Pyrexia (18)
Pneumonia (13)
Dyspnoea (12)
Nausea (12)
Platelet count decreased (12)
Hypoxia (10)
Vomiting (10)
Abdominal pain (9)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)